Media
2019 saw the launch of our new recruitment advertising campaign. Running on a mostly online media strategy, the campaign’s goal was to raise awareness of Chugai’s work on antibody drug research, and how potential candidates can join the CPR team to create a better future. With the promise that “The next big drug discovery is in your hands”, we hope to bring more talented Scientists / Admin staff on board to continue riding on the cutting edge of biopharmaceutical research.
[2019] Dr Tomoyuki Igawa recently gave an introductory lecture to Science undergrads at NUS. You can watch excerpts of this informative and intriguing session in this video.
[2020] In response to the joint press release with A*STAR on the COVID-19 project, our Chairman, Sir David Lane was featured on Channel News Asia – Asia Tonight on 15 May 2020 to discuss more about how antibody approach could be fast effective in developing COVID-19 treatments.
[2020] LabStories is series of employees sharing their real experience at work and CPR’s culture.
Find out more – LabStories
[2020] LabStories is series of employees sharing their real experience at work and CPR’s culture.
Find out more – LabStories
[2021] In this introductory video to CPR, find out how we leverage our collaborative and innovative culture to spark the creation of novel ideas, identify active drug candidates and cultivate excellence in the field of drug discovery.
[2022] At CPR, we constantly strive to push new frontiers in our quest to discover ground-breaking new drugs. Technology-driven transformation is critical to realize our global pharmaceutical aspirations. The COVID-19 pandemic has accelerated our digital transformation journey as we seek to enhance efficiency and speed up the discovery of promising drug candidates. The adoption of Canon Business Services has allowed us to automate and digitise tasks, as well as to process vast amounts of information more efficiently. Using Canon’s scalable and flexible solutions has enabled us to improve operational efficiency so we can focus on what we do best: to discover innovative new drugs that can address unmet medical needs.
[2023] On 23 March 2023, CPR was spotlighted as part of a four-part news series aired in Japan, which focused on Singapore’s science ecosystem and its efforts to attract multinational companies to establish a base here. Broadcast on BS TV Tokyo’s Nikkei News Plus 9, this exciting opportunity showcased CPR’s commitment to innovation and also highlighted our pivotal role in driving advancements in the field of biopharmaceutical research.
Our team welcomed the TV crew into our headquarters in February 2023, offering them a behind-the-scenes look into our state-of-the-art lab facilities and how we conduct our antibody engineering research.
The segment that aired highlighted Biopolis’ vital role in fuelling scientific innovation and collaboration. It explored Singapore’s ambitions to become a global R&D hub by offering sophisticated infrastructure and facilitating information sharing to accelerate drug development.
In an interview broadcast during the segment, our CEO Dr Hideaki Shimada elaborated on the rationale behind setting up operations in Singapore. With 150 staff from 14 countries, Dr Shimada emphasized how this diverse talent pool has served as a catalyst for innovation within CPR. He also highlighted that opportunities for collaborative research between research institutes and other private enterprises have positioned Singapore favourably to further scientific advancements. With Singapore’s scientific ecosystem set up for success, he expressed confidence that Singapore could push new boundaries in R&D.
